Gilead and Achillion Announce Positive Antiviral Activity and Illumina to Present at the Annual Deutsche Bank Securities 2007 Small Cap Growth Conference.

0 Comments | M2 Presswire, February, 2007

M2 PRESSWIRE-12 February 2007-U.S. Equity News: Gilead and Achillion Announce Positive Antiviral Activity and Illumina to Present at the Annual Deutsche Bank Securities 2007 Small Cap Growth Conference(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:12022007 City of Industry, CA - Biotechnology industry alert provided by U.S.

Equity News. Gilead Sciences (Nasdaq: GILD) and Achillion Pharmaceuticals (Nasdaq: ACHN) recently announced their decision to discontinue the development of GS 9132, also known as ACH-806, for the treatment of hepatitis C viral (HCV) infection, based upon preliminary data from a Phase 1b/2 trial. Preliminary data from the first cohort of the Phase 1b/2 trial indicated that the compound demonstrated antiviral activity, validating the novel...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)